抗肺动脉高压药物的抗增生和血管扩张作用的比较分析：大鼠和人体体外广泛研究

IF 3.5 3区医学 Q2 PHARMACOLOGY & PHARMACY

Vascular pharmacology Pub Date : 2024-04-08 DOI:10.1016/j.vph.2024.107371

Daniel Morales-Cano , Bianca Barreira , María Callejo , Miguel A. Olivencia , Antonio Ferruelo , Javier Milara , José Ángel Lorente , Laura Moreno , Ángel Cogolludo , Francisco Perez-Vizcaino

{"title":"抗肺动脉高压药物的抗增生和血管扩张作用的比较分析：大鼠和人体体外广泛研究","authors":"Daniel Morales-Cano , Bianca Barreira , María Callejo , Miguel A. Olivencia , Antonio Ferruelo , Javier Milara , José Ángel Lorente , Laura Moreno , Ángel Cogolludo , Francisco Perez-Vizcaino","doi":"10.1016/j.vph.2024.107371","DOIUrl":null,"url":null,"abstract":"<div><p>An effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI<sub>2</sub> agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferative. 4) quercetin and imatinib were potent dual vasodilator/antiproliferative drugs. 5) Tacrolimus and levosimendan lacked antiproliferative effects. 6) Forskolin, pinacidil and hydroxyfasudil were more effective as antiproliferative in human cells.</p></div>","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human\",\"authors\":\"Daniel Morales-Cano , Bianca Barreira , María Callejo , Miguel A. Olivencia , Antonio Ferruelo , Javier Milara , José Ángel Lorente , Laura Moreno , Ángel Cogolludo , Francisco Perez-Vizcaino\",\"doi\":\"10.1016/j.vph.2024.107371\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>An effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI<sub>2</sub> agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferative. 4) quercetin and imatinib were potent dual vasodilator/antiproliferative drugs. 5) Tacrolimus and levosimendan lacked antiproliferative effects. 6) Forskolin, pinacidil and hydroxyfasudil were more effective as antiproliferative in human cells.</p></div>\",\"PeriodicalId\":23949,\"journal\":{\"name\":\"Vascular pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vascular pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S153718912400096X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S153718912400096X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

有效的肺动脉高压（PH）治疗应结合抗增生和血管扩张作用。我们比较了多种药物在人和大鼠肺动脉平滑肌细胞（PASMC）中的抗增殖和血管扩张作用。主要发现1）已获批准的 PH 药物（PDE5 抑制剂、sGC 兴奋剂和 PGI2 激动剂）是首选的血管扩张剂。2）cGMP 兴奋剂对高血压大鼠的细胞更有效。3）硝苯地平具有同样的血管扩张和抗增殖作用。4）槲皮素和伊马替尼是强效的扩张血管/抗增殖双重药物。5) 他克莫司和左西孟旦缺乏抗增殖作用。6) 福斯可林、吡那地尔和羟法舒地尔对人体细胞的抗增殖作用更有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comparative analysis of antiproliferative and vasodilator effects of drugs for pulmonary hypertension: Extensive in vitro study in rats and human

An effective pulmonary hypertension (PH) treatment should combine antiproliferative and vasodilator effects. We characterized a wide-range of drugs comparing their anti-proliferative vs vasodilator effects in human and rat pulmonary artery smooth muscle cells (PASMC). Key findings: 1) Approved PH drugs (PDE5 inhibitors, sGC stimulators and PGI₂ agonists) are preferential vasodilators. 2) cGMP stimulators were more effective in cells derived from hypertensive rats. 3) Nifedipine acted equally as vasodilator and antiproliferative. 4) quercetin and imatinib were potent dual vasodilator/antiproliferative drugs. 5) Tacrolimus and levosimendan lacked antiproliferative effects. 6) Forskolin, pinacidil and hydroxyfasudil were more effective as antiproliferative in human cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vascular pharmacology 医学-药学

CiteScore

6.60

自引率

2.50%

发文量

153

审稿时长

31 days

期刊介绍： Vascular Pharmacology publishes papers, which contains results of all aspects of biology and pharmacology of the vascular system. Papers are encouraged in basic, translational and clinical aspects of Vascular Biology and Pharmacology, utilizing approaches ranging from molecular biology to integrative physiology. All papers are in English. The Journal publishes review articles which include vascular aspects of thrombosis, inflammation, cell signalling, atherosclerosis, and lipid metabolism.